Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Relatlimab in Advanced Chordoma
NCT03623854Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Apr 2019
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of relatlimab in chordoma, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Objective Response Rate up to 2 years. Started Apr 2019; status: completed.
02
Drugs
relatlimab
03
Conditions
chordoma
Beyond the preview
Go deeper on NCT03623854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623854.